anti-programmed cell death protein 1 antibody expressing pluripotent killer T lymphocytes
Term · Oncology and biomedicine · MLC-T-ONC-011044
A specific population of pluripotent killer (PIK) T cells that have been induced to express high levels of antibodies against the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential antitumor activity. Although the exact mechanism(s) of action through which PIK-PD-1 cells exert their effects has yet to be elucidated, upon infusion, these cells secrete antibodies that target PD-1 expressed on the surface of activated T cells and tumor cells. This may block the interaction of PD-1 with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1; CD274) and PD-1 ligand 2 (PD-L2, PD-1L2; CD273). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation; PD-L1 is overexpressed on certain cancer cells, and PD-L2 is primarily expressed on antigen presenting cells (APCs).
| Identifier | MLC-T-ONC-011044 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-programmed cell death protein 1 antibody expressing pluripotent killer T cells; anti-PDCD1 antibody expressing pluripotent killer T lymphocytes; anti-PD-1 antibody expressing pluripotent killer T lymphocytes; anti-PD-1 antibody expressing pluripotent killer T cells; anti-PDCD1 antibody expressing pluripotent killer T cells |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011044",
"term": "anti-programmed cell death protein 1 antibody expressing pluripotent killer T lymphocytes",
"field": "Oncology and biomedicine",
"definition": "A specific population of pluripotent killer (PIK) T cells that have been induced to express high levels of antibodies against the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential antitumor activity. Although the exact mechanism(s) of action through which PIK-PD-1 cells exert their effects has yet to be elucidated, upon infusion, these cells secrete antibodies that target PD-1 expressed on the surface of activated T cells and tumor cells. This may block the interaction of PD-1 with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1; CD274) and PD-1 ligand 2 (PD-L2, PD-1L2; CD273). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation; PD-L1 is overexpressed on certain cancer cells, and PD-L2 is primarily expressed on antigen presenting cells (APCs).",
"synonyms": [
"anti-programmed cell death protein 1 antibody expressing pluripotent killer T cells",
"anti-PDCD1 antibody expressing pluripotent killer T lymphocytes",
"anti-PD-1 antibody expressing pluripotent killer T lymphocytes",
"anti-PD-1 antibody expressing pluripotent killer T cells",
"anti-PDCD1 antibody expressing pluripotent killer T cells"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-programmed-cell-death-protein-1-antibody-expressing-pluripotent-killer-t/"
}
Record 2,175 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.